Your browser doesn't support javascript.
loading
Oncology Expanded Access and FDA's Project Facilitate.
Scepura, Barbara; Chan, Mitchell; Kim, Tamy; Boehmer, Jessica; Goldberg, Kirsten B; Pazdur, Richard.
Afiliação
  • Scepura B; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Chan M; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Kim T; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Boehmer J; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Goldberg KB; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Oncologist ; 26(10): e1880-e1882, 2021 10.
Article em En | MEDLINE | ID: mdl-34288259
ABSTRACT
The Oncology Center of Excellence at the U.S. Food and Drug Administration launched Project Facilitate on May 31, 2019, to assist oncology health care providers with Expanded Access requests for investigational drugs. Expanded Access, sometimes called "compassionate use," is a regulatory pathway for physicians caring for patients who have a life-threatening condition or a serious disease to gain access to an investigational drug for treatment when no comparable or satisfactory alternative treatment options are available. Herein we describe the Project Facilitate program and the process for requesting Expanded Access to an investigational drug.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Drogas em Investigação / Ensaios de Uso Compassivo Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Drogas em Investigação / Ensaios de Uso Compassivo Idioma: En Ano de publicação: 2021 Tipo de documento: Article